Home
>
National Drug Code (NDC)
>
cilostazol
cilostazol - 60505-2522-8 - (cilostazol)
Drug Information of cilostazol
| Product NDC: | 60505-2522 |
| Proprietary Name: | cilostazol |
| Non Proprietary Name: | cilostazol |
| Active Ingredient(s): | 100 mg/1 & nbsp; cilostazol |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of cilostazol
| Product NDC: | 60505-2522 |
| Labeler Name: | Apotex Corp. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA077030 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20111018 |
Package Information of cilostazol
| Package NDC: | 60505-2522-8 |
| Package Description: | 1000 TABLET in 1 BOTTLE (60505-2522-8) |
NDC Information of cilostazol
| NDC Code | 60505-2522-8 |
| Proprietary Name | cilostazol |
| Package Description | 1000 TABLET in 1 BOTTLE (60505-2522-8) |
| Product NDC | 60505-2522 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | cilostazol |
| Dosage Form Name | TABLET |
| Route Name | ORAL |
| Start Marketing Date | 20111018 |
| Marketing Category Name | ANDA |
| Labeler Name | Apotex Corp. |
| Substance Name | CILOSTAZOL |
| Strength Number | 100 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Phosphodiesterase 3 Inhibitor [EPC],Phosphodiesterase 3 Inhibitors [MoA] |
